Phase 2, single-arm, 26 week trial of eculizumab evaluating time to haematologic and renal improvements in atypical haemolytic uraemic syndrome patients aged 12 years and above with chronic kidney disease.
Latest Information Update: 29 Apr 2014
At a glance
- Drugs Eculizumab (Primary)
- Indications Atypical Haemolytic Uraemic Syndrome
- Focus Therapeutic Use
- 29 Apr 2014 New trial record